// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























28841 Abstracts

Risk Factors for Polyomavirus Infection After Renal Transplantation: Introduction of the Protective Effect of Peritoneal Dialysis.

S. Hosseini-Moghaddam - American Transplant Congress (ATC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Nephrology

N/A

N/A

Safety and Activity of Anti-C1s Humanized Monoclonal Antibody TNT009 in Late Antibody-Mediated Kidney Allograft Rejection – Results of a First-in-Human Phase 1 Trial.

F. Eskandary - American Transplant Congress (ATC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

TNT009

CLOVIZ: Clinical outcomes visualization of IMDC criteria in metastatic renal cell carcinoma for patient-centered decision making.

Anobel Y. Odisho - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Germline DNA repair mutations in metastatic castration-resistant prostate cancer: Therapy response and applicability of circulating tumor DNA.

Werner J. Struss - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Androgen Tear

Proton-pump inhibitors (PPIs) and survival outcomes in patients with metastatic renal cell carcinoma (mRCC).

Aly-Khan A. Lalani - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Serum Phosphorus and Cardiovascular Disease Outcomes, Graft Failure, or Total Mortality in Chronic Kidney Transplant Recipients.

B. Merhi - American Transplant Congress (ATC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

N/A

N/A

AR nuclear localization and microtubule bundling as markers of docetaxel and cabazitaxel sensitivity in metastatic castration-resistant prostate cancer (mCRPC): Prospective biomarker analysis from TAXYNERGY.

Paraskevi Giannakakou - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Cabazitaxel

Significance of Atypical Cytology in the Evaluation of Patients with End Stage Renal Disease for Transplantation.

J. Law - American Transplant Congress (ATC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Nephrology

N/A

N/A

Is there a relationship between testosterone levels at the end of short-term androgen deprivation therapy and outcomes in intermediate risk prostate cancer? Prospective data from a phase III trial.

Abdenour Nabid - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Bicalutamide

Specific Gene Expression Signature of Complement-Activating Donor Specific Anti-HLA Antibody-Mediated Rejection in Kidney Allografts.

C. Lefaucheur - American Transplant Congress (ATC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Interferon Gamma

Clinical activity of PD1/PDL1 inhibitors in metastatic non-clear cell renal cell carcinoma (nccRCC).

Raphael Brandao Moreira - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Real world experience of immuno-oncology agents in metastatic renal cell carcinoma: Results from the IMDC.

Steven Yip - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Pembrolizumab

Analysis of overall survival (OS) based on tumor target lesion change in the phase 3 METEOR trial of cabozantinib (cabo) versus everolimus (eve) in advanced renal cell carcinoma (RCC).

Sumanta K. Pal - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Cabozantinib

Streamlining Discharge Pathways in Kidney Transplant Recipients with Delayed Graft Function.

E. Chan - American Transplant Congress (ATC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Nephrology

N/A

N/A

Real-world outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving second-line (2L) chemotherapy (CT) vs alternative androgen receptor-targeted agents (ARTA) after lack of response to first-line (1L) ARTA in US community oncology practices.

William K. Oh - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Alkaline phosphatase

Substance Use Among Potential Kidney Transplant Candidates and Its Impact on Access to Kidney Transplantation; a Canadian Cohort Study.

E. Tang - American Transplant Congress (ATC) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Population-based analysis of treatment toxicity among men with castration-resistant prostate cancer.

Robert Nam - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Enzalutamide

Survival Outcomes from DCD Transplant Are Comparable to DBD Transplant from Kidneys Procured from Donors > 50 Years of Age. A UNOS/OPTN Propensity Score Matched Pair Analysis.

H. Sharma - American Transplant Congress (ATC) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

The Clinical and Economic Burden of Pneumonia in Canadian Solid Organ Transplant Recipients.

N. Law - American Transplant Congress (ATC) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

The Combined Effects of Induction Regimens and Antiviral Prophylaxis on the Risk of CMV Infection in Different Serostatus Subgroups After Liver Transplantation.

C. Low - American Transplant Congress (ATC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

N/A

TA-9070

Copyright © 2026. QuantiNova All rights reserved